Navidea Biopharma (NAVB) Reports Q4 Loss of $0.11

Navidea Biopharma (NYSE: NAVB) reported Q4 EPS of ($0.11). Revenue for the quarter came in at $1 million, versus $0 reported last year.

For earnings history and earnings-related data on Navidea Biopharma (NAVB) click here.

You May Also Be Interested In

• AI chip winners may face tougher road ahead as hyperscalers catch up: JPM
• Six Flags names Mark Pauls as chief operating officer
• Waste stocks ride AI and healthcare boom as CLH surges 27%